PUBLISHED DATE : Oct 2022 | Pages : 270
Fill out your details & get your free sample
The Global Psoriatic Arthritis Treatment Market Share, Size, & Trends Analysis Report by
270 Pages
8 Tables
169 Charts
3 Regions
8 Countries
16 Companies
6 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size (2027) | USD 12.46 Billion |
| Market Size (2021) | USD 7.81 Billion |
| CAGR (2022-2027) | 8.09% |
| Base Year | 2021 |
| Forecast Year | 2022-2027 |
| Market Segments | Drug Class, Disease Type, Gender Type, Age Group, Severity Type, and Geography |
| Geographic Analysis | North America, Europe, APAC |
| Countries Covered | United States, France, Germany, Italy, UK, Spain, China, and Japan |
| TOTAL PREVALENT CASES IN 8MM (2021) | 2,047,197 |
| COUNTRY WITH HIGHEST PREVALENCE (2021) | China (443,145) |
| COUNTRY WITH HIGHEST INCIDENCE (2021) | China (108,316) |
| TOTAL PIPELINE ASSETS | 26+ Assets (Phase III: 30.77%; Phase II: 23.08%)(Biologics: 69.23%; Small Molecules: 23.70%) |
| TOTAL CLINICAL TRIALS | 150+ Clinical Trials (Completed: 36.36%; Recruiting (20.12%) |
| ANTICIPATED DRUG LAUNCHES IN NEAR FUTURE | Bimekizumab; Tildrakizumab; Neihulizumab; SHR-1314 and Others |
The global psoriatic arthritis treatment market is expected to reach USD 12.46 billion by 2027, from USD 7.81 billion in 2021, growing at a CAGR of 8.09%. Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory rheumatic disease characterized by pain, stiffness, swollen joints, joint erosion, and bone formation. Psoriatic arthritis occurs in up to 30% of patients with psoriasis, most commonly those aged between 30 and 60 years. It starts about 10 years after psoriasis develops for many people, but some develop PsA first or without ever developing or noticing psoriasis. PsA can occur at any age and affects men and women equally. In recent years, women have contributed more to the global psoriatic arthritis treatment market as they are at greater risk of developing psoriatic arthritis. According to estimates, in the European Union, PsA affects more than 2 million people, and in the United States, about 0.5 million.
The exact cause of PsA is not yet known. Family history plays a strong role; about 40% of those with the disease have a family member with psoriasis or arthritis. Risk factors can include obesity, severe psoriasis, nail disease, and trauma or deep lesions at sites of trauma.
Psoriatic Arthritis Diagnosis:
There’s no specific test to diagnose psoriatic arthritis. The symptoms are similar to other arthritic diseases such as rheumatoid arthritis, reactive arthritis, and gout. Imaging techniques such as X-rays, CT scans, ultrasound, MRI, and skin biopsies may all be used for diagnosis.
Psoriatic Arthritis Treatment:
Treatment depends on the extent of pain, swelling, and stiffness. Those with very mild arthritis may require treatment only when their joints are painful and may stop therapy when they feel better. The major types of treatment for psoriatic arthritis are Non-steroidal anti-inflammatory drugs such as ibuprofen (Motrin or Advil) or naproxen (Aleve) as initial treatment. If arthritis does not respond, disease-modifying anti-rheumatic drugs may be prescribed. These include sulfasalazine (Azulfidine), methotrexate (Rheumatrex, Trexall, Otrexup, Rasuvo), cyclosporine (Neoral, Sandimmune, Gengraf), and leflunomide. Sometimes combinations of these drugs may be used together. Azathioprine (Imuran) may help those with severe forms of PSA.
Other treatments include biologics, typically starting with TNF inhibitors such as adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi), infliximab (Remicade). Other biologics used for PsA include the IL-17A inhibitors secukinumab (Cosentyx) and ixekizumab (Taltz); IL-12/23 inhibitor ustekinumab (Stelara); IL-23 inhibitors risankizumab-rzaa (Skyrizi) and guselkumab (Tremfya) or other classes abatacept (Orencia). Newer oral medications, such as tofacitinib (Xeljanz), upadacitinib (Rinvoq), and apremilast (Otezla), have also been shown to be effective.
The psoriatic arthritis treatment market portfolio contains a total of 25+ assets that are in various phases of development. Most industry-sponsored drugs in active clinical development for psoriatic arthritis are in the Phase III stage. The emerging therapeutics for psoriatic arthritis include Bimekizumab, Tildrakizumab, SHR-0302, Neihulizumab, and many others. Launching these novel emerging drugs will shift the PsA treatment paradigm in the near future. With more than 25 molecules in various stages of development, it is expected that new vendors are likely to enter the industry with a novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating psoriatic arthritis.
Psoriatic Arthritis: Clinical Trials Scenario
The clinical trial portfolio contains 150+ trials in various development phases. Most industry-sponsored drugs in active clinical development for PsA are in the Phase III stage. The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for psoriatic arthritis have been in the late phase of development, with 58% of trials in Phase II/III & III and only 41% in Phase Phase I-II.
Increasing Adoption of Biological Therapies
Biological therapies such as anti-tumor necrosis factor (TNF) and anti-interleukin antibodies are widely used in the psoriatic arthritis treatment market. With Stelara being biologic approved for PsA in 2013, there is a demand for therapies with novel MOAs that are less immunogenic than current offerings. Many new classes of therapies are looking to enter the psoriatic arthritis treatment market over the next few years. The biologics such as interleukin inhibitors are making inroads into the psoriatic arthritis market owing to better clinical profile and convenient patient dosing.
Anticipated Launch of Emerging Drugs
A recent wave of biologic products prescribed for psoriatic arthritis treatment will likely create lucrative opportunities. Despite the plethora of therapies currently available to patients with psoriatic arthritis (PsA), there is still room for improvement within the psoriatic arthritis treatment market space.
Arizton anticipates the launch of five new agents among the 8MM, including two interleukins (IL) inhibitors (Bimekizumab; Tildrakizumab) and two oral Janus kinase (JAK) inhibitors (Filgotinib and SHR0302) and one oral tyrosine kinase 2 (TYK2) inhibitor (Deucravacitinib). Launching these late-stage drugs will create an opportunity for growth in the global psoriatic arthritis treatment market.
Focus on Novel Drugs with Novel Mechanism
Over the past seven years, agents that block inflammatory pathways other than tumor necrosis factor (TNF) represent new options for treating psoriasis arthritis (PsA). The therapeutic agents targeting the IL-23/IL-17 axis have been proven to be very effective in psoriatic arthritis, some are already in the therapeutic armamentarium, and others are in development. IL-23/IL-17 axis cytokines are essential players in the pathogenesis of psoriasis and PsA. Inhibition of IL-23 and IL-17 with monoclonal antibodies is a very effective therapy in the psoriatic arthritis treatment market. Over the next five years, Arizton expects to see a surge of innovation emerging from the research and development pipeline and a range of technology-enabled transformations that will expand the evidence-basis for interventions and bring measurable improvements to outcomes.
The U.S. dominates the global psoriatic arthritis treatment market by geography due to the healthcare affordability in the U.S., the knowledge and awareness amongst the people, and the technological advancement in this region. However, Germany is expected to grow faster with a high CAGR in the PsA drug industry due to the rise in access and quality of healthcare, increased awareness about disease management, and rising healthcare expenditure in this region. The trend of biosimilars in emerging markets, such as China and Japan, could potentially alter this region's psoriatic arthritis therapeutic landscape.
According to Arizton estimates, the prevalent cases of psoriatic arthritis were high in China, followed by Spain and the U.K. in 2020. The increasing prevalence of psoriatic arthritis is driving the growth of the psoriatic arthritis treatment market. According to estimates, more than two million people in European Union were affected by PsA in 2014.
The global psoriatic arthritis treatment market is dominated by many companies offering generic drugs and selective pharma/biotech companies offering patented/commercial drugs for treating PsA. The U.S. Food and Drug Administration (FDA) approved the interleukin antibody Stelara (Ustekinumab) for treating psoriatic arthritis in 2013. Recently the FDA approved interleukins such as Skyrizi (risankizumab-rzaa) in 2022 and Cosentyx (secukinumab) in 2021 for treating PsA. Although generic products continue to capture significant psoriatic arthritis treatment market share, the arrival of biologics and other targeted therapies indicate a paradigm shift in this therapeutic space through the forecast period.
Companies such as AbbVie Inc., Johnson & Johnson, Takeda Pharmaceutical Co Ltd, Biogen Inc, UCB SA, Amgen, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, and Novartis are the major players in the global psoriatic arthritis treatment market. These players are focused on adopting growth strategies to strengthen their product portfolio. These companies have adopted strategies such as collaborations & acquisitions, expansion of geographical footprint, investments in research & development, and manufacture of novel drugs to compete in the global psoriatic arthritis treatment market.
The other prominent players operating in the psoriatic arthritis treatment market include Sun Pharmaceuticals, Bausch Health Companies Inc, Jiangsu HengRui Medicine Co. Ltd, Biocad Biopharmaceutical, Meiji Holdings Co Ltd, and Bio-Thera. These players are focused on R&D initiatives for developing technologically advanced and innovative psoriatic drugs and are also entering collaborations to maintain their position in the industry.
Frequently Asked Questions
How big is the global psoriatic arthritis treatment market?
The global psoriatic arthritis treatment market size is expected to reach USD 12.46 billion by 2027.
What is the growth rate of the global psoriatic arthritis treatment market?
The global psoriatic arthritis treatment market is growing with a CAGR of 8.09% from 2022-2027.
What factors drive the growth of the psoriatic arthritis treatment market?
The increasing adoption of biological therapies, the anticipated launch of emerging drugs, and the focus on novel drugs with novel mechanisms are prime factors driving the market.
Who are the leading vendors operating in the psoriatic arthritis treatment market?
Companies such as AbbVie Inc., Johnson & Johnson, Takeda Pharmaceutical Co Ltd, Biogen Inc, UCB SA, Amgen, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, and Novartis are the major players in the global psoriatic arthritis treatment market. These players are focused on adopting growth strategies to strengthen their product portfolio.
Which region holds the largest share in the global psoriatic arthritis treatment market?
The U.S. dominates the global psoriatic arthritis treatment market by geography due to the healthcare affordability in the U.S., the knowledge and awareness amongst the people, and the technological advancement in this region.
The global psoriatic arthritis treatment market is expected to grow at a CAGR of approximately 8.09% from 2022 to 2027.
The following factors are likely to contribute to the growth of the psoriatic arthritis treatment market during the forecast period:
Base Year: 2021
Forecast Year: 2022-2027
The report considers the present scenario of the global psoriatic arthritis treatment market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.
Key Vendors
Other Prominent Vendors
Key Emerging Vendors with Late Stage Pipeline Drugs
Segmentation by Drug Class
Segmentation by Disease Type
Segmentation by Gender Type
Segmentation by Age Group
Segmentation by Severity Type
Segmentation by Geography
Exhibit 1: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 2: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN 8 MAJOR MARKETS (2018 – 2020)
Exhibit 3: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 4: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 5: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 6: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 7: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 8: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 9: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 10: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 11: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 12: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN US (2018 – 2027)
Exhibit 13: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN US (2018 – 2020)
Exhibit 14: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN US (2021 – 2027)
Exhibit 15: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN US (2018 – 2027)
Exhibit 16: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN US (2018 – 2027)
Exhibit 17: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN US (2018 – 2027)
Exhibit 18: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN US (2018 – 2027)
Exhibit 19: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN US (2018 – 2027)
Exhibit 20: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN US (2018 – 2027)
Exhibit 21: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN US (2018 – 2027)
Exhibit 22: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN US (2018 – 2027)
Exhibit 23: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN CHINA (2018 – 2027)
Exhibit 24: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN CHINA (2018 – 2020)
Exhibit 25: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN CHINA (2021 – 2027)
Exhibit 26: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN CHINA (2018 – 2027)
Exhibit 27: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN CHINA (2018 – 2027)
Exhibit 28: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN CHINA (2018 – 2027)
Exhibit 29: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN CHINA (2018 – 2027)
Exhibit 30: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN CHINA (2018 – 2027)
Exhibit 31: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN CHINA (2018 – 2027)
Exhibit 32: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN CHINA (2018 – 2027)
Exhibit 33: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN CHINA (2018 – 2027)
Exhibit 34: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN JAPAN (2018 – 2027)
Exhibit 35: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN JAPAN (2018 – 2020)
Exhibit 36: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN JAPAN (2021 – 2027)
Exhibit 37: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN JAPAN (2018 – 2027)
Exhibit 38: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN JAPAN (2018 – 2027)
Exhibit 39: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN JAPAN (2018 – 2027)
Exhibit 40: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN JAPAN (2018 – 2027)
Exhibit 41: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN JAPAN (2018 – 2027)
Exhibit 42: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN JAPAN (2018 – 2027)
Exhibit 43: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORITIC ARTHRITIS BY AGE GROUP IN JAPAN (2018 – 2027)
Exhibit 44: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN JAPAN (2018 – 2027)
Exhibit 45: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN GERMANY (2018 – 2027)
Exhibit 46: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN GERMANY (2018 – 2020)
Exhibit 47: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN GERMANY (2021 – 2027)
Exhibit 48: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN GERMANY (2018 – 2027)
Exhibit 49: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN GERMANY (2018 – 2027)
Exhibit 50: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIAYTIC ARTHRITIS BY AGE GROUP IN GERMANY (2018 – 2027)
Exhibit 51: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN GERMANY (2018 – 2027)
Exhibit 52: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN GERMANY (2018 – 2027)
Exhibit 53: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN GERMANY (2018 – 2027)
Exhibit 54: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN GERMANY (2018 – 2027)
Exhibit 55: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN GERMANY (2018 – 2027)
Exhibit 56: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN UK (2018 – 2027)
Exhibit 57: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN UK (2018 – 2020)
Exhibit 58: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN UK (2021 – 2027)
Exhibit 59: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN UK (2018 – 2027)
Exhibit 60: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN UK (2018 – 2027)
Exhibit 61: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN UK (2018 – 2027)
Exhibit 62: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN UK (2018 – 2027)
Exhibit 63: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN UK (2018 – 2027)
Exhibit 64: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN UK (2018 – 2027)
Exhibit 65: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN UK (2018 – 2027)
Exhibit 66: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN UK (2018 – 2027)
Exhibit 67: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN FRANCE (2018 – 2027)
Exhibit 68: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN FRANCE (2018 – 2020)
Exhibit 69: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN FRANCE (2021 – 2027)
Exhibit 70: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN FRANCE (2018 – 2027)
Exhibit 71: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN FRANCE (2018 – 2027)
Exhibit 72: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN FRANCE (2018 – 2027)
Exhibit 73: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN FRANCE (2018 – 2027)
Exhibit 74: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN FRANCE (2018 – 2027)
Exhibit 75: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN FRANCE (2018 – 2027)
Exhibit 76: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN FRANCE (2018 – 2027)
Exhibit 77: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN FRANCE (2018 – 2027)
Exhibit 78: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN ITALY (2018 – 2027)
Exhibit 79: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN ITALY (2018 – 2020)
Exhibit 80: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN ITALY (2021 – 2027)
Exhibit 81: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN ITALY (2018 – 2027)
Exhibit 82: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN ITALY (2018 – 2027)
Exhibit 83: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN ITALY (2018 – 2027)
Exhibit 84: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN ITALY (2018 – 2027)
Exhibit 85: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN ITALY (2018 – 2027)
Exhibit 86: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN ITALY (2018 – 2027)
Exhibit 87: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN ITALY (2018 – 2027)
Exhibit 88: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN ITALY (2018 – 2027)
Exhibit 89: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN SPAIN (2018 – 2027)
Exhibit 90: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN SPAIN (2018 – 2020)
Exhibit 91: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF PSORIATIC ARTHRITIS IN SPAIN (2021 – 2027)
Exhibit 92: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN SPAIN (2018 – 2027)
Exhibit 93: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN SPAIN (2018 – 2027)
Exhibit 94: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN SPAIN (2018 – 2027)
Exhibit 95: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN SPAIN (2018 – 2027)
Exhibit 96: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF PSORIATIC ARTHRITIS BY DISEASE TYPE IN SPAIN (2018 – 2027)
Exhibit 97: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY SEVERITY TYPE IN SPAIN (2018 – 2027)
Exhibit 98: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY AGE GROUP IN SPAIN (2018 – 2027)
Exhibit 99: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF PSORIATIC ARTHRITIS BY GENDER TYPE IN SPAIN (2018 – 2027)
Exhibit 100: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 101: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET SNAPSHOT IN 8 MAJOR MARKETS (2018 – 2020)
Exhibit 102: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DISEASE TYPE IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 103: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY GENDER TYPE IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 104: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DRUG CLASS IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 105: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY AGE GROUP IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 106: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY SEVERITY IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 107: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET IN US (2021 – 2027)
Exhibit 107: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET SNAPSHOT IN US (2018 – 2020)
Exhibit 108: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DISEASE TYPE IN US (2021 – 2027)
Exhibit 109: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY GENDER TYPE IN US (2021 – 2027)
Exhibit 110: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DRUG CLASS IN US (2021 – 2027)
Exhibit 111: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY AGE GROUP IN US (2021 – 2027)
Exhibit 106: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY SEVERITY IN US (2021 – 2027)
Exhibit 112: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET IN CHINA (2021 – 2027)
Exhibit 113: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET SNAPSHOT IN CHINA (2018 – 2020)
Exhibit 114: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DISEASE TYPE IN CHINA (2021 – 2027)
Exhibit 115: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY GENDER TYPE IN CHINA (2021 – 2027)
Exhibit 116: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DRUG CLASS IN CHINA (2021 – 2027)
Exhibit 117: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY AGE GROUP IN CHINA (2021 – 2027)
Exhibit 106: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY SEVERITY IN CHINA (2021 – 2027)
Exhibit 118: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET IN GERMANY (2021 – 2027)
Exhibit 119: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET SNAPSHOT IN GERMANY (2018 – 2020)
Exhibit 120: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DISEASE TYPE IN GERMANY (2021 – 2027)
Exhibit 121: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY GENDER TYPE IN GERMANY (2021 – 2027)
Exhibit 122: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DRUG CLASS IN GERMANY (2021 – 2027)
Exhibit 123: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY AGE GROUP IN GERMANY (2021 – 2027)
Exhibit 106: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY SEVERITY IN GERMANY (2021 – 2027)
Exhibit 124: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET IN JAPAN (2021 – 2027)
Exhibit 125: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET SNAPSHOT IN JAPAN (2018 – 2020)
Exhibit 126: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DISEASE TYPE IN JAPAN (2021 – 2027)
Exhibit 127: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY GENDER TYPE IN JAPAN (2021 – 2027)
Exhibit 128: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DRUG CLASS IN JAPAN (2021 – 2027)
Exhibit 129: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY AGE GROUP IN JAPAN (2021 – 2027)
Exhibit 106: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY SEVERITY IN JAPAN (2021 – 2027)
Exhibit 130: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET IN FRANCE (2021 – 2027)
Exhibit 131: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET SNAPSHOT IN FRANCE (2018 – 2020)
Exhibit 132: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DISEASE TYPE IN FRANCE (2021 – 2027)
Exhibit 133: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY GENDER TYPE IN FRANCE (2021 – 2027)
Exhibit 134: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DRUG CLASS IN FRANCE (2021 – 2027)
Exhibit 135: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY AGE GROUP IN FRANCE (2021 – 2027)
Exhibit 106: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY SEVERITY IN FRANCE (2021 – 2027)
Exhibit 136: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET IN ITALY (2021 – 2027)
Exhibit 137: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET SNAPSHOT IN ITALY (2018 – 2020)
Exhibit 138: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DISEASE TYPE IN ITALY (2021 – 2027)
Exhibit 139: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY GENDER TYPE IN ITALY (2021 – 2027)
Exhibit 140: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DRUG CLASS IN ITALY (2021 – 2027)
Exhibit 141: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY AGE GROUP IN ITALY (2021 – 2027)
Exhibit 106: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY SEVERITY IN ITALY (2021 – 2027)
Exhibit 142: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET IN UK (2021 – 2027)
Exhibit 143: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET SNAPSHOT IN UK (2018 – 2020)
Exhibit 144: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DISEASE TYPE IN UK (2021 – 2027)
Exhibit 145: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY GENDER TYPE IN UK (2021 – 2027)
Exhibit 146: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DRUG CLASS IN UK (2021 – 2027)
Exhibit 147: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY AGE GROUP IN UK (2021 – 2027)
Exhibit 106: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY SEVERITY IN UK (2021 – 2027)
Exhibit 148: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET IN SPAIN (2021 – 2027)
Exhibit 149: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET SNAPSHOT IN SPAIN (2018 – 2020)
Exhibit 150: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DISEASE TYPE IN SPAIN (2021 – 2027)
Exhibit 151: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY GENDER TYPE IN SPAIN (2021 – 2027)
Exhibit 152: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY DRUG CLASS IN SPAIN (2021 – 2027)
Exhibit 153: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY AGE GROUP IN SPAIN (2021 – 2027)
Exhibit 106: HISTORIC & PROJECTED REVENUE OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET BY SEVERITY IN SPAIN (2021 – 2027)
Exhibit 154: MARKETED DRUGS OVERVIEW IN PSORIATIC ARTHRITIS MARKET
Exhibit 155: MARKETED DRUGS OVERVIEW SNAPSHOT IN PSORIATIC ARTHRITIS TREATMENT
Exhibit 156: PIPELINE DRUGS OVERVIEW IN PSORIATIC ARTHRITIS TREATMENT MARKET
Exhibit 157: PSORIATIC ARTHRITIS PIPELINE DRUGS OVERVIEW BY DISEASE TYPE
Exhibit 158: PSORIATIC ARTHRITIS PIPELINE DRUGS OVERVIEW BY DEVELOPMENT PHASE
Exhibit 159: PSORIATIC ARTHRITIS PIPELINE DRUGS OVERVIEW BY ROUTE OF ADMINISTRATION
Exhibit 160: PSORIATIC ARTHRITIS PIPELINE DRUGS OVERVIEW BY MECHANISM OF ACTION
Exhibit 161: PSORIATIC ARTHRITIS PIPELINE DRUGS OVERVIEW BY MOLECULE TYPE
Exhibit 162: PSORIATIC ARTHRITIS PIPELINE DRUGS OVERVIEW BY GEOGRAPHY TYPE
Exhibit 163: PSORIATIC ARTHRITIS CLINICAL TRIAL ANALYSIS SNAPSHOT
Exhibit 164: PSORIATIC ARTHRITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY RECRUITMENT STATUS
Exhibit 165: PSORIATIC ARTHRITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY PRODUCT TYPE
Exhibit 166: PSORIATIC ARTHRITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY ROUTE OF ADMINISTRATION
Exhibit 167: PSORIATIC ARTHRITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY MOLECULE TYPE
Exhibit 168: PSORIATIC ARTHRITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY GEOGRAPHY TYPE
Exhibit 169: COMPETITIVE ASSESSMENT OF PSORIATIC ARTHRITIS THERAPEUTICS MARKET
LIST OF TABLES
Table 1: KEY MARKET DRIVERS IN PSORIATIC ARTHRITIS MARKET
Table 2: KEY MARKET CONSTRAINTS IN PSORIATIC ARTHRITIS MARKET
Table 3: KEY MARKET TRENDS IN PSORIATIC ARTHRITIS TREATMENT MARKET
Table 4: KEY TENTATIVE TIMELINE APPROVALS OF PIPELINE DRUGS IN PSORIATIC ARTHRITIS
Table 5: KEY REGULATORY DESIGNATIONS OF PIPELINE DRUGS IN PSORIATIC ARTHRITIS
Table 6: KEY MILESTONES IN PSORIATIC ARTHRITIS MARKET
Table 7: KEY DEALS & COLLABORATIONS IN PSORIATIC ARTHRITIS MARKET
Table 8: KEY INACTIVE/DISCONTINUED PRODUCTS IN PSORIATIC ARTHRITIS TREATMENT
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
